BCAX

AI MemoPost-earnings T+1

Bicara Therapeutics

As of 2026-11-10/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-11-10 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Metastatic colorectal cancer cohort data • 2027-01-31

Base target: $11 / p=45% prob

Biggest risk

Q3 R&D expense rose to $56.5 million from $33.0 million and net loss to $71.2 million from $36.3 million. Genmab's competing Phase 3 result intensified differentiation risk; Goldman downgraded Bicara to Sell with an $8 target before this earnings print. [#SEC-8K-2026-11-09] (Bicara earnings exhibit; Goldman coverage)

Invalidation

Break below $5 or thesis failure.

What would change my mind?

Substantial FORTIFI-HN01 enrollment and stated funding into the first half of 2029 preserve a path to the mid-2027 interim analysis. Stifel retained Buy after the print, though it cut its target to $43 from $45. [#SEC-8K-2026-11-09] (Bicara earnings exhibit; Stifel coverage)

Research note

Recommendation

—

Confidence

medium

As of

2026-11-10

Base target

$11

p=45%

Bull target

$18

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

December translational data presentation
FORTIFI-HN01 interim results after Q3 enrollment progress
Substantial FORTIFI-HN01 enrollment and stated funding into the first half of 2029 preserve a path to the mid-2027 interim analysis.

BearKey bullets

Early colorectal and preclinical data may not translate into registrational outcomes.
FORTIFI-HN01 efficacy and safety remain unproven in the pivotal randomized study; an unfavorable mid-2027 interim result could cause substantial downside.
Genmab's positive Phase 3 petosemtamab results could limit ficerafusp alfa's differentiation and commercial share, even if Bicara's own trial succeeds.

WatchKey bullets

Metastatic colorectal cancer cohort data

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $11 (p=45%)

Target spread vs base: +64% / -55%

Scenario probabilities

Bull Target: $18 (p=25%)Base Target: $11 (p=45%)Bear Target: $5 (p=30%)

Commentary

Mixed T+1 follow-up: BCAX closed November 9 at $9.98, up 15.38% from November 6, but the close alone cannot establish why it rose or whether the reaction will hold. (Price history) Stifel's post-print $45-to-$43 target cut cites higher operating-expense estimates; reliable post-print consensus surprise and broader estimate-revision data were not established. (Stifel coverage) Low coverage and competing clinical data temper the positive deterministic prior. Numeric zeros in unavailable sentiment fields are placeholders, not observed neutral readings.

As of 2026-11-10 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

December translational data presentation
FORTIFI-HN01 interim results after Q3 enrollment progress

Scenarios

Bull Target (Scenario probability)

$18 / p=25% prob

Base Target (Scenario probability)

$11 / p=45% prob

Bear Target (Scenario probability)

$5 / p=30% prob

Analysis 2026-11-10 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-01-31
Metastatic colorectal cancer cohort data
Bicara plans January 2027 Phase 1b expansion-cohort data for ficerafusp alfa alone and with pembrolizumab in a specified later-line colorectal cancer population. This may test potential beyond head-and-neck cancer, but the cohort is early-stage. [#SEC-8K-2026-11-09] (Bicara earnings exhibit)
Prob 65.00% • Move 12.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

December translational data presentation
2026-12-16
Bicara plans preclinical ficerafusp alfa data on fibrosis and drug penetration at the December 14–16 ESMO Immuno-Oncology & Advanced Therapies Congress. This is a lower-signal mechanistic update, not patient efficacy evidence. [#SEC-8K-2026-11-09] (Bicara earnings exhibit)
Prob 80% • Move 3% • Priced-in 50%

Long-term Catalysts

Months to a year

FORTIFI-HN01 interim results after Q3 enrollment progress
2027-06-30
Bicara reported substantial pivotal-trial enrollment with topline interim results expected in mid-2027. Q3 cash and securities of $442.3 million support its stated runway into the first half of 2029, but neither enrollment nor runway establishes clinical success. Competitive differentiation is now a central question. [#SEC-8K-2026-11-09] (Bicara earnings exhibit)
Prob 60% • Move 25% • Priced-in 40%

Risks

Early colorectal and preclinical data may not translate into registrational outcomes.
FORTIFI-HN01 efficacy and safety remain unproven in the pivotal randomized study; an unfavorable mid-2027 interim result could cause substantial downside.
Genmab's positive Phase 3 petosemtamab results could limit ficerafusp alfa's differentiation and commercial share, even if Bicara's own trial succeeds. (Genmab release)
Higher trial and commercial-preparation spending increases cash consumption; Bicara's runway projection depends on current plans. [#SEC-8K-2026-11-09]

Peers

Symbol	Summary
GMAB	Direct competitive reference in first-line recurrent/metastatic head-and-neck cancer, not a market-cap valuation peer. Genmab reported positive Phase 3 petosemtamab survival and response results; its trial population differs from Bicara's HPV-negative focus. (Genmab release)
NBTX	Prior-baseline head-and-neck oncology comparison, but differing modality and development arrangements make valuation read-through weak.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-11-10